Passage Bio Inc
General ticker "PASG" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $46.4M
Passage Bio Inc does not follow the US Stock Market performance with the rate: -26.2%.
Estimated limits based on current volatility of 3.6%: low 0.63$, high 0.67$
Factors to consider:
- Company does not operate outside North America (retrieved using AI)
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.65$, 2.06$]
- 2024-12-30 to 2025-12-30 estimated range: [0.79$, 2.34$]
Financial Metrics affecting the PASG estimates:
- Negative: Non-GAAP EPS, $ of -1.86 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -66.50 <= 2.35
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term PASG quotes
Long-term PASG plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
Operating Expenses | $185.73MM | $138.39MM | $108.39MM |
Operating Income | $-185.73MM | $-138.39MM | $-108.39MM |
Non-Operating Income | $0.34MM | $2.27MM | $6.33MM |
R&D Expense | $117.67MM | $86.05MM | $61.42MM |
Income(Loss) | $-185.39MM | $-136.12MM | $-102.06MM |
Profit(Loss) | $-185.39MM | $-136.12MM | $-102.06MM |
Stockholders Equity | $318.66MM | $201.37MM | $111.28MM |
Assets | $355.08MM | $243.55MM | $150.54MM |
Operating Cash Flow | $-126.88MM | $-118.21MM | $-78.26MM |
Capital expenditure | $25.64MM | $5.27MM | $0.15MM |
Investing Cash Flow | $-45.81MM | $25.20MM | $65.24MM |
Financing Cash Flow | $166.66MM | $-1.35MM | $0.14MM |
Earnings Per Share* | $-3.59 | $-2.51 | $-1.86 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.